Safety and Immunogenicity after a 30-Month Boost of a Subtype C ALVAC-HIV (vcp2438) Vaccine Prime Plus Bivalent Subtype C Gp120/mf59 Vaccine Boost (HVTN 100): A Phase 1-2 Randomized Double-Blind Placebo-Controlled Trial.Vimla Naicker,Fatima Laher,Linda-Gail Bekker,Kelly E Seaton,Mary Allen,Stephen De Rosa,Nicole L Yates,Nonhlanhla N Mkhize,Kevin Saunders,Jack Heptinstall,Mookho Malahleha,Kathryn Mngadi,Brodie Daniels,Craig Innes,Chenchen Yu,Tandile Modise,Valerie Bekker,Nicole Grunenberg, Briana Furch,Maurine D Miner,Sanjay Phogat,Carlos A Diazgranados,Sanjay Gurunathan,Marguerite Koutsoukos,Olivier Van Der Meeren,Alison C Roxby,Guido Ferrari,Lynn Morris,David Montefiori,M Juliana McElrath,Georgia D Tomaras,Zoe MoodiePLOS global public health（2024）引用 0|浏览10AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
